PUT/ELI LILLY & CO/500/0.1/20.09.24 | Market Closed - BOERSE MUENCHEN 19:26:22 05/07/2024 BST | ||
| 0.035 EUR | -10.26% |
|
| Current month | +40.00% | ||
| 1 month | -60.67% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 05/07/24 | 0.035 | -10.26% |
| 04/07/24 | 0.039 | -2.50% |
| 03/07/24 | 0.04 | 0.00% |
| 02/07/24 | 0.04 | +11.11% |
| 01/07/24 | 0.036 | +44.00% |
Real-time BOERSE MUENCHEN
Last update July 05, 2024 at 07:26 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | Goldman Sachs |
| WKN | GG5ZKG |
| ISIN | DE000GG5ZKG7 |
| Date issued | 27/03/2024 |
| Strike | 500 $ |
| Maturity | 20/09/2024 (77 Days) |
| Parity | 10 : 1 |
| Emission price | 0.26 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.364 € |
|---|---|
| Lowest since issue | 0.023 € |
| Spread | 0.15 € |
| Spread % | 88.24% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
914.6
USD
Average target price
870.3
USD
Spread / Average Target
-4.84%
- Stock Market
- Warrants
- Warrant
